Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 6/20 | 0.41 |
| ▸ | KIT | P10721 | 5/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775905 | 0.80 | LRRK2 (0.46) | LRRK2KDM4EALDH1A1MAPTCREBBP | |
| SCHEMBL3771457 | 0.78 | GRM4 (0.62) | LRRK2BRD4CREBBPGRM4CYP1A2 | |
| SCHEMBL13060922 | 0.77 | MAPT (0.45) | LRRK2ALDH1A1MAPTGRM4 | |
| SCHEMBL3778709 | 0.77 | KDR (0.47) | KDRPDGFRAKDM4EALDH1A1MAPT | |
| SCHEMBL3774841 | 0.76 | KMT2A (0.52) | LRRK2KDRKDM4EALDH1A1GRM4 | |
| SCHEMBL3774932 | 0.76 | LRRK2 (0.66) | LRRK2 | |
| SCHEMBL3769990 | 0.76 | LRRK2 (0.42) | LRRK2KDRKDM4EALDH1A1MAPT | |
| SCHEMBL3770441 | 0.76 | GRM4 (0.61) | LRRK2ALDH1A1MAPTGRM4 | |
| SCHEMBL381085 | 0.76 | GRM4 (0.62) | LRRK2KDRNOTUMBRD4CREBBP | |
| SCHEMBL3775329 | 0.75 | LRRK2 (0.61) | LRRK2KDRMAPTGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | LRRK2 2309/4885KDR 797/4885KIT 2078/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | LRRK2 2208/4885KDR 726/4885KIT 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.